Results 111 to 120 of about 5,288 (183)

A Case Series and Literature Review on Zanubrutinib Therapy for the Treatment of Relapsed/Refractory Immune Thrombocytopenia

Cancer Reports
Background Immune thrombocytopenia (ITP) is an acquired autoimmune disease characterised by low platelet count. Treatment discontinuation or heterogeneity in the pathogenesis of ITP heightens the occurrence of relapsed or refractory ITP.
Bingjie Ding, Mengjuan Li, Liu Liu, Xuewen Song, Yuanyuan Zhang, Ao Xia, Jingyuan Liu, Hu Zhou   +7 more
doaj   +1 more source

Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants. [PDF]

Clin Transl Sci, 2023
Ucpinar S, Smith PF, Long L, Li F, Yan H, Wadhwa J, Chu KA, Shu J, Nunn P, Li M.   +9 more
europepmc   +1 more source

Division of Analysis of Homeostasis [PDF]

, 2007
この論文は国立情報学研究所の学術雑誌公開支援事業により電子化されまし
永井 博弌
core   +1 more source

Regulatory Mechanism of PTP-PEST for IgE Fc Receptor Signaling [PDF]

, 2010
連続したくしゃみ、止まらない鼻水などやっかいな症状で悪名の高い所謂「アレルギー」を直接引き起こす細胞は、マスト細胞もしくは好塩基球である。マスト細胞は、IgE 受容体 (FcεR) を介して活性化され、顆粒中に蓄えた炎症物質放出と炎症性サイトカインの合成・放出によりアレルギー性炎症を惹起する。この細胞内シグナル伝達において、種々のタンパク質中のチロシンリン酸化と脱リン酸化制御が重要な働きをしている。我々は、以前、マスト細胞のFcεRシグナルにおける各種チロシン脱リン酸化酵素(PTP ...
片桐 達雄, 鈴木 望美
core   +1 more source

Targeting lipid metabolism overcomes BTK inhibitor resistance in diffuse large B-cell lymphoma

Medicine in Novel Technology and Devices
Exploring novel therapeutic targets of Diffuse large B cell lymphoma (DLBCL) to overcome its resistance to Bruton's Tyrosine Kinase (BTK) inhibitors is a key topic.
Zhuojun Liu, Chenyue Wu, Zhaohua Yao, Yuxuan Wang, Zhe Yu, Jian Yu   +5 more
doaj   +1 more source

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial. [PDF]

ACR Open Rheumatol, 2023
Wallace DJ, Dörner T, Pisetsky DS, Sanchez-Guerrero J, Patel AC, Parsons-Rich D, Le Bolay C, Drouin EE, Kao AH, Guehring H, Dall'Era M.   +10 more
europepmc   +1 more source

Characterizing immunomodulatory properties of a novel therapeutic approach for multiple sclerosis - Inhibition of Bruton's tyrosine kinase [PDF]

Multiple Sclerosis is a complex and challenging chronic disease of the central nervous system (CNS), characterized by inflammation, demyelination, and neurodegeneration.
Dybowski, Sarah
core   +1 more source

Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny [PDF]

Bruton tyrosine kinase (Btk) has long been known to play a key role in chronic lymphatic leukaemia, Waldenström macroglobulinaemia and other B-cell proliferative disorders.
Camilli, Massimiliano, Menna, Pierantonio   +1 more
core   +1 more source

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor. [PDF]

Pharmacol Res Perspect, 2021
Zhang H, Ou YC, Su D, Wang F, Wang L, Sahasranaman S, Tang Z.   +6 more
europepmc   +1 more source

P1603: EFFICACY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITOR ZANUBRUTINIB IN ITP

HemaSphere, 2023
Qiu-Sha Huang, Hai-Xia Fu, Chen-Cong Wang, Xiao-Lu Zhu, Yun He, Qi Chen, Jin Wu, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Hui Zhang   +9 more
doaj   +1 more source